Arovella Therapeutics Ltd has released a press release.
Quarterly Activities/Appendix 4C Cash Flow Report
Earlier from Arovella Therapeutics
- Arovella Therapeutics: appoints former CSL CSO Dr Andrew Nash as Non-executive Director
- Positive FDA Type D Meeting Outcome
- CLDN18.2 CAR-T cells eliminate pancreatic cancer cells